TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04998409

Intervention type: DEVICE
Intervention: Monofocal lens
Description: not applicable as patients are already implanted with the monofocal lens
Study: NCT05223556

Intervention type: DEVICE
Intervention: Full Self-Diagnostic device in a remote diagnostic imaging site
Description: Full Self-Diagnostic CRP+OCT imaging, followed by online consultation

Intervention type: DEVICE
Intervention: Human imager operated diagnostic device in the hospital
Description: Human imager operated CRP imaging with dilated pupils, followed by face-to-face consultation
Study: NCT05224895

Intervention type: PROCEDURE
Intervention: General Anesthesia in Trendelenburg position for robotic prostatectomy
Description: in this arm, changes in preoperative and postoperative airway measurements and correlation with postoperative critical airway events will be monitored.
Study: NCT06408909

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Pharmacist Intervention Group
Description: Group to which the clinical pharmacist makes recommendations The drugs administered to patients during scheduled hospital visits will be recorded. A detailed medication review will be conducted by the clinical pharmacist. As a result of a comprehensive evaluation, recommendations were made to doctors regarding drug-related problems and were recorded.
Study: NCT06262711

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Vitamin C 500mg hydroxypropyl methylcellulose (HPMC) capsules (Solgar UK).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Vitamin C 500mg hydroxypropyl methylcellulose (HPMC) capsules (Solgar UK).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Vitamin C-matched placebo capsule. Placebo capsules manufactured using hydroxypropyl methylcellulose (HPMC) capsules and microcrystalline cellulose (MCC).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Vitamin C-matched placebo capsule. Placebo capsules manufactured using hydroxypropyl methylcellulose (HPMC) capsules and microcrystalline cellulose (MCC).
Study: NCT06050096

Intervention type: PROCEDURE
Intervention: PCI
Description: CTO patients treated by DCB
Study: NCT05441553

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: VGB-R04
Description: A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor IX variant
Study: NCT06360965

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Improved warm meridians and relieve pain plaster
Description: Starting from the 1st to 3rd day after the menstrual cycle is clean, apply it 6-8 hours before bedtime every day, with one day off. Apply 10 times per menstrual cycle as one course of treatment, with two consecutive courses of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Traditional warm meridians and relieve pain plaster
Description: The treatment course is the same as the improved warm meridians and relieve pain plaster group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plaster
Description: The treatment course is the same as the improved warm meridians and relieve pain plaster group.
Study: NCT05973461

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise and virtual reality
Description: Riding a cycle ergometer while experiencing virtual reality

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Riding a cycle ergometer
Description: Riding on a cycle ergometer without experiencing virtual reality
Study: NCT04819139

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Excersises
Description: Active thumb exercises
Study: NCT06119685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy
Study: NCT04819139

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Excersises
Description: Active thumb exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reeducation ADL
Description: Reeducation in the activities daily life

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reeducation ADL
Description: Reeducation in the activities daily life

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Joint protection
Description: Used of a thumb orthosis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Joint protection
Description: Used of a thumb orthosis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioception exercises
Description: Specific proprioception exercises
Study: NCT06521190

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACOU085 (bimokalner)
Description: Transtympanic injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Transtympanic injection
Study: NCT06119685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy
Study: NCT06483906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax, Azacitidine and Homoharringtonine
Description: Patients will receive the VAH regimen for the treatment of AML
Study: NCT05547256

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Variant (Omicron BA.5) mRNA Vaccine Low dose
Description: 50μg/dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Variant (Omicron BA.5) mRNA Vaccine High dose
Description: 100μg/dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline solution
Study: NCT06597292

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vision improvement
Description: Vision improvement for patients with refractive disorders (hyperopia and presbyopia)
Study: NCT06609200

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture needles
Description: The acupuncture needles and related equipment will have already received approval for routine Traditional Chinese Medicine (TCM) clinical practice in Singapore.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Acupuncture needles
Description: The acupuncture needles and related equipment will have already received approval for routine Traditional Chinese Medicine (TCM) clinical practice in Singapore.
Study: NCT06612138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pilates exercises
Description: the patients will receive pilates exercises in the form of breathing exercises, chest lift, bridging, mermaid, swan, quadruped exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: yoga exercises
Description: the patients will receive yoga in the form of Bhastrikā: rapid and powerful inhalations and exhalations by means of the force of the diaphragm, letting the air sound when exhaling, Nāḏī Śoḏhana: from Sanskrit, nadi means \&#39;to channel\&#39; and shodhana means \&#39;purify, cleanse\&#39;, o Hand position Mrigi mudra: It consists of flexing the index and ring fingers of the hand, o Breathing: Gently close the right nostril with the thumb, inhale fingers and exhale slowly through the right. Keeping your right nostril open, inhale, close it, and slowly open and exhale through the left. This is a cycle. Repeat 3-5 times and then release the hand mudra and return to normal breathing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tai chi exercises
Description: the patients will receive tai chi in the form of Commencing form, Repulse Monkey,Grasp Peacock's Tail,Move Hands like Moving Clouds (left side only), Fair Lady Works at Shuttles, Golden Cock Stands on One Leg (left and right),Brush Knees and Twist Steps, Closing form.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tradional physical therapy
Description: Patients will receive traditional physiotherapy breathing, massage and relaxation exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tradional physical therapy
Description: Patients will receive traditional physiotherapy breathing, massage and relaxation exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tradional physical therapy
Description: Patients will receive traditional physiotherapy breathing, massage and relaxation exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tradional physical therapy
Description: Patients will receive traditional physiotherapy breathing, massage and relaxation exercises
Study: NCT06613373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib
Description: Dalpiciclib: 150 mg (p.o.) was given once daily for 3 weeks, followed by 1 week off in each 4-week cycle.
Study: NCT06119685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Chemoprotectant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Chemoprotectant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Chemoprotectant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Chemoprotectant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Chemoprotectant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Chemoprotectant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Anti-CD38 antibody therapy
Study: NCT06613191

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Participant will be on aspirin alone or P2Y12 inhibitor alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)
Description: Participant will be taking either P2Y12 inhibitor at time of colonoscopy
Study: NCT06473207

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote ischemic post conditioning sessions
Description: Three sessions of RIPOST (within the 4 hours following cardiac arrest and then 12 and 24 hours after cardiac arrest), as follows: four cycles of cuff inflation to 200 mmHg for 5 min and then deflation to 0 mmHg for another 5 min (40 min total duration of the intervention), using an inflatable thigh tourniquet

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham sessions
Description: Three sessions of a sham procedure (within the 4 hours following cardiac arrest and then 12 and 24 hours after cardiac arrest), as follows : application of a thigh tourniquet during 40 min without any inflation
Study: NCT06434441

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous bone augmentation
Description: Maxillary alveolar bone reconstruction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous bone augmentation
Description: Maxillary alveolar bone reconstruction
Study: NCT06612450

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: turbinate surgery
Description: Turbinoplasty to decrease the turbinate size in cases with turbinate hypertrophy with mainly soft tissue component without sacrificing the mucosal function

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: turbinate surgery
Description: Turbinoplasty to decrease the turbinate size in cases with turbinate hypertrophy with mainly soft tissue component without sacrificing the mucosal function
Study: NCT06611943

Intervention type: BEHAVIORAL
Intervention: DietCoach
Description: Participants are invited to give at least one dietary recommendation to a patient\&#39;s food purchase data using the DietCoach platform.

Intervention type: BEHAVIORAL
Intervention: DietCoach
Description: Participants are invited to give at least one dietary recommendation to a patient\&#39;s food purchase data using the DietCoach platform.

Intervention type: BEHAVIORAL
Intervention: DietCoach
Description: Participants are invited to give at least one dietary recommendation to a patient\&#39;s food purchase data using the DietCoach platform.
Study: NCT06612411

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B. subtilis
Description: 2 capsules, 3 times a day, orally taken for one month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dead B. subtilis
Description: 2 capsules, 3 times a day, orally taken for one month
Study: NCT06612398

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preoperative preparation video
Description: An animated video illustrating the story of a child's journey through the hospital facilities, including the anaesthesia induction, and the postoperative return home.
Study: NCT06612242

Intervention type: PROCEDURE
Intervention: early tracheostomy (less than 7 days from intubation)
Description: Early tracheostomy (less than 7 days from ventilation) in mechanically ventilated patients with Guiilain-Barre syndrome

Intervention type: PROCEDURE
Intervention: Late tracheostomy (more than 7 days from intubation)
Description: Late tracheostomy (more than 7 days from ventilation) in mechanically ventilated patients with Guiilain-Barre syndrome
Study: NCT06612619

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dyad instruction
Description: Rather than being instructed solo or one-on-one the trainees are instructed in pairs of two (dyad).
Study: NCT06612359

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BOOST GAIT Program
Description: In addition to usual care, participants will undergo additional therapy over a four-week period, with sessions occurring five times per week for one hour. The BOOST GAIT sessions will be conducted as group-based therapy with four patients and two physiotherapists present to oversee the performance of mobility-specific exercises, including sit-to-stand transfers, standing and stepping, and eventually walking.
Study: NCT05632263

Intervention type: DIAGNOSTIC_TEST
Intervention: EHMRGscore
Description: validation of the EHMRG score for hospitalized patients with acute heart failure in the emergency department
Study: NCT04658693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implanted Multi contact stimulating electrode and intramuscular electromyography recording electrode
Description: See arm description
Study: NCT05877586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CLARE app
Description: CLARE will contain materials on hospital discharge preparation, Covid care, and caregiver self-care, all of which have already been vetted by the DUHS Patient and Family Education department. Existing CLARE teaching on Covid covers isolation; quarantine; home sanitization; and monitoring for Covid symptoms such as cough, fever, fatigue, and shortness of breath. All will be reviewed and amended to reflect the latest CDC guidelines for Covid care at the time of pilot implementation. CLARE will also include reminders on examining the After-Visit-Summary to determine home medications and information on follow-up care.~CLARE will have two sessions of training and support to caregivers that can be delivered before hospital discharge and daily for seven days after discharge.
Study: NCT05224661

Intervention type: OTHER
Intervention: Prospective determination of the clinical utility of measurable residual disease (MRD) testing
Description: Prospective determination of the clinical utility of measurable residual disease (MRD) testing for relapse and survival of patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (alloHCT).
Study: NCT06649045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orforglipron
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study: NCT05995353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous (SC) Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous (SC) Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous (SC) Injection
Study: NCT04721197

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Egg vouchers
Description: 30-day egg vouchers will be provided monthly, in addition to standard of care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants will continue to receive the standard of care. No egg vouchers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Participants will continue to receive the standard of care. No egg vouchers.
Study: NCT05449444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib 4.5 mg/kg/day
Description: Masitinib 4.5 mg/kg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best supportive care
Description: Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, sodium cromoglicate, antidepressants, antileukotrienes, proton pump inhibitors, and corticosteroids.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best supportive care
Description: Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, sodium cromoglicate, antidepressants, antileukotrienes, proton pump inhibitors, and corticosteroids.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best supportive care
Description: Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, sodium cromoglicate, antidepressants, antileukotrienes, proton pump inhibitors, and corticosteroids.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib 6.0 mg/kg/day
Description: Masitinib 6.0 mg/kg/day
Study: NCT03734523

Intervention type: COMBINATION_PRODUCT
Intervention: Flourish Vaginal Care System
Description: This is not technically an intervention. All women who enroll in the study will be those who have opted to use the Flourish Vaginal Care System. This system is comprised of a vaginal wash (Balance), an intravaginal moisturizing gel (Restore), and a vaginal probiotic supplement (BiopHresh). Balance will be used daily. Restore will be used every other day. BiopHresh will be used twice a week with Restore. All products will be started after the first visit and continue throughout the 6-month study.

Intervention type: COMBINATION_PRODUCT
Intervention: Flourish Vaginal Care System
Description: This is not technically an intervention. All women who enroll in the study will be those who have opted to use the Flourish Vaginal Care System. This system is comprised of a vaginal wash (Balance), an intravaginal moisturizing gel (Restore), and a vaginal probiotic supplement (BiopHresh). Balance will be used daily. Restore will be used every other day. BiopHresh will be used twice a week with Restore. All products will be started after the first visit and continue throughout the 6-month study.
Study: NCT05897372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib
Description: Standard of care for diabetic kidney disease.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib
Description: Standard of care for diabetic kidney disease.
Study: NCT05076877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib tablets will be administered orally, alone or in combination with probe substrates.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam (cytochrome P450 3A4 \[CYP3A4\] substrate) will be administered orally as a syrup as a part of probe substrates.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin (breast cancer resistant protein \[BCRP\] substrate) tablet will be administered orally as a part of probe substrates.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin (organic cation transporter 1 \[OCT1\] substrate) will be administered orally as a syrup as a part of probe substrates.
Study: NCT05705921

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy standard
Description: Standard moderately hypofractionated radiotherapy in prostate cancer

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy Hypo-FLAME
Description: Ultra-hypofractionated focal lesion ablative microboost in prostate cancer
Study: NCT05995353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous (SC) Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous (SC) Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous (SC) Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous (SC) Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous (SC) Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous (SC) Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous (SC) Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous (SC) Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous (SC) Injection
Study: NCT06306638

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and tissue sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and tissue sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and tissue sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endobronchial Ultrasound Bronchoscopy
Description: Undergo EBUS

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endobronchial Ultrasound Bronchoscopy
Description: Undergo EBUS

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endobronchial Ultrasound Bronchoscopy
Description: Undergo EBUS